South Korea · Delayed Price · Currency is KRW Korean Drug Statistics
Total Valuation
Korean Drug has a market cap or net worth of KRW 46.43 billion. The enterprise value is 21.19 billion.
| Market Cap | 46.43B |
| Enterprise Value | 21.19B |
Important Dates
The next estimated earnings date is Thursday, November 27, 2025.
| Earnings Date | Nov 27, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Korean Drug has 10.91 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 10.91M |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +1.76% |
| Owned by Insiders (%) | 50.60% |
| Owned by Institutions (%) | n/a |
| Float | 5.39M |
Valuation Ratios
The trailing PE ratio is 12.96.
| PE Ratio | 12.96 |
| Forward PE | n/a |
| PS Ratio | 0.74 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | 5.20 |
| P/OCF Ratio | 4.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.91, with an EV/FCF ratio of 2.37.
| EV / Earnings | 5.97 |
| EV / Sales | 0.34 |
| EV / EBITDA | 3.91 |
| EV / EBIT | 6.22 |
| EV / FCF | 2.37 |
Financial Position
The company has a current ratio of 7.94, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.94 |
| Quick Ratio | 5.53 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 856.24 |
Financial Efficiency
Return on equity (ROE) is 4.53% and return on invested capital (ROIC) is 2.71%.
| Return on Equity (ROE) | 4.53% |
| Return on Assets (ROA) | 2.33% |
| Return on Invested Capital (ROIC) | 2.71% |
| Return on Capital Employed (ROCE) | 4.15% |
| Revenue Per Employee | 232.39M |
| Profits Per Employee | 13.15M |
| Employee Count | 270 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 1.71 |
Taxes
In the past 12 months, Korean Drug has paid 756.97 million in taxes.
| Income Tax | 756.97M |
| Effective Tax Rate | 17.58% |
Stock Price Statistics
The stock price has decreased by -6.25% in the last 52 weeks. The beta is 0.28, so Korean Drug's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -6.25% |
| 50-Day Moving Average | 4,406.10 |
| 200-Day Moving Average | 4,695.00 |
| Relative Strength Index (RSI) | 46.37 |
| Average Volume (20 Days) | 13,801 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Korean Drug had revenue of KRW 62.74 billion and earned 3.55 billion in profits. Earnings per share was 328.41.
| Revenue | 62.74B |
| Gross Profit | 27.77B |
| Operating Income | 3.41B |
| Pretax Income | 4.31B |
| Net Income | 3.55B |
| EBITDA | 5.41B |
| EBIT | 3.41B |
| Earnings Per Share (EPS) | 328.41 |
Balance Sheet
The company has 25.29 billion in cash and 48.18 million in debt, giving a net cash position of 25.25 billion or 2,313.54 per share.
| Cash & Cash Equivalents | 25.29B |
| Total Debt | 48.18M |
| Net Cash | 25.25B |
| Net Cash Per Share | 2,313.54 |
| Equity (Book Value) | 79.13B |
| Book Value Per Share | 7,314.94 |
| Working Capital | 57.22B |
Cash Flow
In the last 12 months, operating cash flow was 9.74 billion and capital expenditures -806.77 million, giving a free cash flow of 8.93 billion.
| Operating Cash Flow | 9.74B |
| Capital Expenditures | -806.77M |
| Free Cash Flow | 8.93B |
| FCF Per Share | 818.51 |
Margins
Gross margin is 44.26%, with operating and profit margins of 5.43% and 5.66%.
| Gross Margin | 44.26% |
| Operating Margin | 5.43% |
| Pretax Margin | 6.86% |
| Profit Margin | 5.66% |
| EBITDA Margin | 8.63% |
| EBIT Margin | 5.43% |
| FCF Margin | 14.23% |
Dividends & Yields
This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 3.73%.
| Dividend Per Share | 160.00 |
| Dividend Yield | 3.73% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 48.75% |
| Buyback Yield | -0.22% |
| Shareholder Yield | 3.51% |
| Earnings Yield | 7.64% |
| FCF Yield | 19.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korean Drug has an Altman Z-Score of 5.56 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.56 |
| Piotroski F-Score | 5 |